These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
4414 results:

  • 1. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
    Osumi H; Shinozaki E; Nakamura Y; Esaki T; Yasui H; Taniguchi H; Satake H; Sunakawa Y; Komatsu Y; Kagawa Y; Denda T; Shiozawa M; Satoh T; Nishina T; Goto M; Takahashi N; Kato T; Bando H; Yamaguchi K; Yoshino T
    Nat Commun; 2024 Jul; 15(1):5885. PubMed ID: 39003289
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Targeting in colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Current and Emerging Treatment Paradigms in colorectal cancer: Integrating Hallmarks of cancer.
    Salva de Torres C; Baraibar I; Saoudi González N; Ros J; Salva F; Rodríguez-Castells M; Alcaraz A; García A; Tabernero J; Élez E
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000083
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.
    Bajpai P; Agarwal S; Afaq F; Al Diffalha S; Chandrashekar DS; Kim HG; Shelton A; Miller CR; Singh SK; Singh R; Varambally S; Nagaraju GP; Manne A; Paluri R; Khushman M; Manne U
    J Exp Clin Cancer Res; 2024 Jul; 43(1):192. PubMed ID: 38992681
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Novel 1,3,4-oxadiazole derivatives of naproxen targeting egfr: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
    Chen S; Gu J; Wu K; Zhao X; Lu Y
    Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of colorectal cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-egfr and Anti-VEGF Therapies.
    Popovici D; Stanisav C; Sima LV; Negru A; Murg SI; Carabineanu A
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929620
    [No Abstract]    [Full Text] [Related]  

  • 9. KRASFormer: a fully vision transformer-based framework for predicting
    Singh VK; Makhlouf Y; Sarker MMK; Craig S; Baena J; Greene C; Mason L; James JA; Salto-Tellez M; O'Reilly P; Maxwell P
    Biomed Phys Eng Express; 2024 Jul; 10(5):. PubMed ID: 38925106
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. FAK loss reduces BRAF
    Gao C; Ge H; Kuan SF; Cai C; Lu X; Esni F; Schoen RE; Wang JH; Chu E; Hu J
    Elife; 2024 Jun; 13():. PubMed ID: 38921956
    [No Abstract]    [Full Text] [Related]  

  • 11. The receptor protein tyrosine phosphatase PTPRK promotes intestinal repair and catalysis-independent tumour suppression.
    Young KA; Wojdyla K; Lai T; Mulholland KE; Aldaz Casanova S; Antrobus R; Andrews SR; Biggins L; Mahler-Araujo B; Barton PR; Anderson KR; Fearnley GW; Sharpe HJ
    J Cell Sci; 2024 Jul; 137(14):. PubMed ID: 38904097
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Cohen R; Raeisi M; Chibaudel B; Shi Q; Yoshino T; Zalcberg JR; Adams R; Cremolini C; Van Cutsem E; Heinemann V; Tabernero J; Punt CJA; Arnold D; Hurwitz HI; Douillard JY; Venook AP; Saltz LB; Maughan TS; Kabbinavar F; Bokemeyer C; Grothey A; Mayer RJ; Kaplan R; Tebbutt NC; Randolph Hecht J; Giantonio BJ; Díaz-Rubio E; Sobrero AF; Peeters M; Koopman M; Goldberg RM; Andre T; de Gramont A
    Eur J Cancer; 2024 Aug; 207():114160. PubMed ID: 38896997
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Novel Lipid Nanocomplex Co-Carrying Bcl2 siRNA and Quantum Dots for EGF Receptor-Targeted Anti-cancer Theranosis.
    Choi MJ; Kang SJ; Lee YK; Choi KC; Lee DH; Jeong HY; Kim MW; Kim KS; Park YS
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892434
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeted Treatment against cancer Stem Cells in colorectal cancer.
    Martínez-Pérez J; Torrado C; Domínguez-Cejudo MA; Valladares-Ayerbes M
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892410
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
    J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genome-wide DNA methylation status is a predictor of the efficacy of anti-egfr antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
    Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Proteomic Analysis of Caco-2 Cells Disrupted by EcN 1917-Derived OMVs Reveals Molecular Information on Bacteria-Mediated cancer Cell Migration.
    Zhao L; Zhao M; Wang X; Jia C
    J Proteome Res; 2024 Jul; 23(7):2505-2517. PubMed ID: 38845157
    [No Abstract]    [Full Text] [Related]  

  • 19. Prevalence of Potentially Pathogenic Germline Variants Among Adult Patients in the Philippines With Solid Malignancies Who Underwent Tumor Genomic Profiling.
    Franco PI; Andal JJ; Ang DC; Que FV
    JCO Glob Oncol; 2024 Jun; 10():e2400019. PubMed ID: 38843470
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Brexpiprazole Prevents the Malignant Progression of Human colorectal cancer Cells and Increases Its Sensitivity to egfr Inhibition.
    Long X; Liu X; Xia W; Liu L; Chen W
    Front Biosci (Landmark Ed); 2024 May; 29(5):174. PubMed ID: 38812296
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 221.